Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Media Capital Technologies (MCT) and The Horror Section will fully finance and produce “Ice Cream Man,” Eli Roth’s new horror film. Roth, a master of the genre whose work includes the ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Looking ahead, Eli Lilly narrowed its full-year guidance. It now expects fiscal 2025 EPS in the range of $20.78 to $22.28, falling short of the $22.40 analysts had penciled in. Revenue is ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. Wegovy was first to market but ...

Michael Nagle / Bloomberg via Getty Images Shares of Eli Lilly (LLY) fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that ...

Eli Lilly shares fall as the drug maker lowers its full-year profit outlook, despite topping first-quarter estimates as demand for the company's weight loss drug surged.

Eli Lilly (LLY) stock is sinking as investors react to concerns around GLP-1 drugs and industry dynamics. Red Brook Advisors managing partner Syed Husain joins Catalysts to discuss the market ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank more than 11% in trading despite the win. The ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 45.2% year on year to $12.73 billion. The company ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.